Terms: = Brain cancer AND Neurokinin AND Treatment
20 results:
1. neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract] [Full Text] [Related]
2. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract] [Full Text] [Related]
3. neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B; Trower M; Duggal A; Guglielmini P; Harris P; Jackson D; Lacouture ME; Ratti E; Tonini G; Wood A; Ständer S
BMJ Open; 2020 Feb; 10(2):e030114. PubMed ID: 32034016
[TBL] [Abstract] [Full Text] [Related]
4. Managing vasomotor symptoms in women after cancer.
Pinkerton JV; Santen RJ
Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
[TBL] [Abstract] [Full Text] [Related]
5. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract] [Full Text] [Related]
6. In vitro evaluation of
Majkowska-Pilip A; Rius M; Bruchertseifer F; Apostolidis C; Weis M; Bonelli M; Laurenza M; Królicki L; Morgenstern A
Chem Biol Drug Des; 2018 Jul; 92(1):1344-1356. PubMed ID: 29611298
[TBL] [Abstract] [Full Text] [Related]
7. Managing Menopausal Symptoms and Associated Clinical Issues in Breast cancer Survivors.
Santen RJ; Stuenkel CA; Davis SR; Pinkerton JV; Gompel A; Lumsden MA
J Clin Endocrinol Metab; 2017 Oct; 102(10):3647-3661. PubMed ID: 28934376
[TBL] [Abstract] [Full Text] [Related]
8. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Navari RM
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
[TBL] [Abstract] [Full Text] [Related]
9. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles.
Martinez VG; O'Driscoll L
Clin Chem; 2015 Mar; 61(3):471-82. PubMed ID: 25605682
[TBL] [Abstract] [Full Text] [Related]
10. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract] [Full Text] [Related]
11. Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.
Duggin K; Tickle K; Norman G; Yang J; Wang C; Cross SJ; Gajjar A; Mandrell B
J Pediatr Oncol Nurs; 2014; 31(5):277-83. PubMed ID: 24972782
[TBL] [Abstract] [Full Text] [Related]
12. Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.
Rock EM; Limebeer CL; Parker LA
Exp Brain Res; 2014 Aug; 232(8):2511-34. PubMed ID: 24792499
[TBL] [Abstract] [Full Text] [Related]
13. neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP).
Mou L; Kang Y; Zhou Y; Zeng Q; Song H; Wang R
J Biol Chem; 2013 Jan; 288(1):306-18. PubMed ID: 23166329
[TBL] [Abstract] [Full Text] [Related]
14. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract] [Full Text] [Related]
15. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).
Malherbe P; Ballard TM; Ratni H
Expert Opin Ther Pat; 2011 May; 21(5):637-55. PubMed ID: 21417773
[TBL] [Abstract] [Full Text] [Related]
16. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Akazawa T; Kwatra SG; Goldsmith LE; Richardson MD; Cox EA; Sampson JH; Kwatra MM
J Neurochem; 2009 May; 109(4):1079-86. PubMed ID: 19519779
[TBL] [Abstract] [Full Text] [Related]
17. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
Kneifel S; Bernhardt P; Uusijärvi H; Good S; Plasswilm L; Buitrago-Téllez C; Müller-Brand J; Mäcke H; Merlo A
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1388-95. PubMed ID: 17265035
[TBL] [Abstract] [Full Text] [Related]
18. treatment of nausea and vomiting: gaps in our knowledge.
Sanger GJ; Andrews PL
Auton Neurosci; 2006 Oct; 129(1-2):3-16. PubMed ID: 16934536
[TBL] [Abstract] [Full Text] [Related]
19. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S; Cordier D; Good S; Ionescu MC; Ghaffari A; Hofer S; Kretzschmar M; Tolnay M; Apostolidis C; Waser B; Arnold M; Mueller-Brand J; Maecke HR; Reubi JC; Merlo A
Clin Cancer Res; 2006 Jun; 12(12):3843-50. PubMed ID: 16778112
[TBL] [Abstract] [Full Text] [Related]
20. Decreases in neurokinin-3 tachykinin receptor-immunoreactive and -mRNA levels are associated with salt appetite in the deoxycorticosterone-treated rat.
Lucas LR; Reagan LP; Akama KT; Ma LY; Tamashiro KL; Sakai RR; McEwen BS
Brain Res; 2003 Jan; 960(1-2):252-8. PubMed ID: 12505679
[TBL] [Abstract] [Full Text] [Related]
